Andrographis ： Upper Respiratory Tract Infections

Q: Does Andrographis help with Upper Respiratory Tract Infections?

Based on 7 studies with 800 participants, there is moderate evidence from clinical studies that Andrographis may support Upper Respiratory Tract Infections management. Our evidence grade is B (Good Evidence).

Q: How much Andrographis should I take for Upper Respiratory Tract Infections?

Studies have used various dosages. A commonly studied range is 400 mg 3x/day for up to 7 days. Always consult your healthcare provider before starting any supplement regimen.

Q: Are there side effects of Andrographis?

Reported side effects may include Gastrointestinal discomfort (nausea, diarrhea), Headache, Fatigue, Allergic reactions (rare). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.

Q: How strong is the evidence for Andrographis and Upper Respiratory Tract Infections?

We rate the evidence as Grade B (Good Evidence). This rating is based on 7 peer-reviewed studies with 800 total participants. The overall direction of effect is positive.

Multiple randomized controlled trials and Cochrane-reviewed meta-analyses support andrographis for reducing the severity and duration of upper respiratory symptoms. One of the most evidence-backed herbal supplements for acute respiratory infections.

𝕏 LinkedIn

<\/script>\n

`; }, get iframeSnippet() { const domain = 'immunecited.com'; const params = 'ingredient\u003Dandrographis\u0026condition\u003Dupper\u002Drespiratory\u002Dinfections'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style

Widget powered by . Free, no account required.

結論

Key Study Findings

Randomized Controlled Trial n=331 1.0 weeks Double-blind

Efficacy and safety of AP-Bio®(KalmCold®) in participants with uncomplicated upper respiratory tract viral infection (common …

Dose: 200 mg/day vs: placebo Outcome: URTI symptom severity 効果: None p = 0.034

対象集団: Participants with uncomplicated URTI

Review

A Comprehensive Review of Andrographis paniculata (Burm. f.) Nees and Its Constituents as Potential Lead …

Dose: None vs: None Outcome: URTI symptom severity 効果: None None

対象集団: COVID-19/URTI patients

Review

Plant-Based Support of Respiratory Health during Viral Outbreaks.

Dose: None vs: None Outcome: None 効果: None None

対象集団: None

Other n=179

Early intervention with Kan Jang® to treat upper-respiratory tract infections: A randomized, quadruple-blind study.

Dose: 60 mg vs: placebo Outcome: None 効果: None p = 0.0053

対象集団: None

Meta-Analysis n=1000

Safety of Andrographis paniculata: A systematic review and meta-analysis.

Dose: 95% vs: control Outcome: None 効果: None None

対象集団: upper respiratory tract infection

Other

In vitro anti-biofilm activity of 14-deoxy-11,12-didehydroandrographolide from Andrographis paniculata against Pseudomonas aeruginosa.

Dose: 6 μg/mL vs: Control group Outcome: None 効果: None None

対象集団: None

Key Statistics

研究数

800

参加者数

↑

Positive

グレード

Referenced Papers

Efficacy and safety of AP-Bio®(KalmCold®) in participants with uncomplicated upper respiratory tract viral infection (common cold) - A phase III, … RCT

Complementary therapies in … 2023 6 件の引用

A Comprehensive Review of Andrographis paniculata (Burm. f.) Nees and Its Constituents as Potential Lead Compounds for COVID-19 Drug Discovery. Review

Molecules (Basel, Switzerland) 2022 80 件の引用

Plant-Based Support of Respiratory Health during Viral Outbreaks. Other

Journal of agricultural … 2022 9 件の引用

Safety of Andrographis paniculata: A systematic review and meta-analysis. Meta-Analysis

Pharmacoepidemiology and drug … 2021 32 件の引用

Early intervention with Kan Jang® to treat upper-respiratory tract infections: A randomized, quadruple-blind study. Other

Journal of traditional … 2021 9 件の引用

In vitro anti-biofilm activity of 14-deoxy-11,12-didehydroandrographolide from Andrographis paniculata against Pseudomonas aeruginosa. Other

Brazilian journal of … 2020 45 件の引用

Inhibition of AIM2 inflammasome-mediated pyroptosis by Andrographolide contributes to amelioration of radiation-induced lung inflammation and fibrosis. Other

Cell death & … 2019 160 件の引用

A review for the neuroprotective effects of andrographolide in the central nervous system. Review

Biomedicine & pharmacotherapy … 2019 103 件の引用

A randomized double blind placebo controlled clinical evaluation of extract of Andrographis paniculata (KalmCold) in patients with uncomplicated upper respiratory … RCT

Phytomedicine : international … 2010 107 件の引用

Colds and influenza: a review of diagnosis and conventional, botanical, and nutritional considerations. Review

Alternative medicine review … 2007 163 件の引用

Complementary and alternative medicine for upper-respiratory-tract infection in children. Review

American journal of … 2006 51 件の引用

Andrographis paniculata in the treatment of upper respiratory tract infections: a systematic review of safety and efficacy. Systematic Review

Planta medica 2004 262 件の引用

Andrographis paniculata in the symptomatic treatment of uncomplicated upper respiratory tract infection: systematic review of randomized controlled trials. Systematic Review

Journal of clinical … 2004 157 件の引用

Respiratory and allergic diseases: from upper respiratory tract infections to asthma. Review

Primary care 2002 56 件の引用

Undetectable anti-bacterial activity of Andrographis paniculata (Burma) wall. ex ness. RCT

Journal of the … 1990

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

一般的な使用量

acute:: 400 mg 3x/day for up to 7 days
general:: 200 mg standardized extract (30% andrographolides) 2x/day

上限量： No established UL; short-term use (<14 days)

研究で検討された用量

用量	期間	効果	N
200 mg/day	1.0 weeks	Positive	331
None	--	Positive	--
None	--	Mixed	--
60 mg	--	Positive	179
95%	--	Neutral	1000
6 μg/mL	--	Positive	--
None	--	Mixed	--
18 G	4.0 weeks	Mixed	--

推奨摂取タイミング： At first sign of symptoms; with meals

Safety & Side Effects

報告されている副作用

⚠ Gastrointestinal discomfort (nausea, diarrhea)
⚠ Headache
⚠ Fatigue
⚠ Allergic reactions (rare)
⚠ Potential anti-fertility effects (high doses in animal studies)

既知の相互作用

● Anticoagulant and antiplatelet drugs (may increase bleeding risk)
● Antihypertensive medications (additive blood pressure lowering)
● Immunosuppressant medications (may counteract immunosuppression)

耐容上限摂取量： No established UL; short-term use (<14 days)

サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。

Frequently Asked Questions

Does Andrographis help with Upper Respiratory Tract Infections?

Based on 7 studies with 800 participants, there is moderate evidence from clinical studies that Andrographis may support Upper Respiratory Tract Infections management. Our evidence grade is B (Good Evidence).

How much Andrographis should I take for Upper Respiratory Tract Infections?

Studies have used various dosages. A commonly studied range is 400 mg 3x/day for up to 7 days. Always consult your healthcare provider before starting any supplement regimen.

Are there side effects of Andrographis?

Reported side effects may include Gastrointestinal discomfort (nausea, diarrhea), Headache, Fatigue, Allergic reactions (rare). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.

How strong is the evidence for Andrographis and Upper Respiratory Tract Infections?

We rate the evidence as Grade B (Good Evidence). This rating is based on 7 peer-reviewed studies with 800 total participants. The overall direction of effect is positive.

Related Evidence

に関する他の成分： Upper Respiratory Tract Infections

Vitamin D A Zinc A Beta-Glucan A Vitamin C B Echinacea B Garlic B

総合評価

Evidence Strength72%

High confidence

研究の内訳

RCT (3)Meta (1)Other (3)

代替成分との比較

この症状に対する他の成分との比較をご覧ください。

に関するすべての成分を見る： Upper Respiratory Tract Infections

詳しく見る

FDAに関する免責事項: これらの記述は米国食品医薬品局（FDA）による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。